Bown, Abbie;
Peto, Tim;
Sweed, Angela;
Catton, Matthew;
Nelthorpe-Cowne, Joshua;
Benford, Tracy;
LFD laboratory team, .;
... Vipond, Richard; + view all
(2025)
Laboratory evaluation of 185 commercial assays for detecting SARS-CoV-2: the UK response for mass testing.
EClinicalMedicine
, Article 103416. 10.1016/j.eclinm.2025.103416.
(In press).
Preview |
Text
Walker_ Laboratory evaluation of 185 commercial assays_ PIIS2589537025003487.pdf Download (904kB) | Preview |
![]() |
Text
Supplementary material.docx - Accepted Version Download (472kB) |
Abstract
Background: In August 2020, Public Health England and Oxford University were commissioned to design and deliver (with NHS Test and Trace, NHSTT) a rapid evaluation programme of antigen Lateral Flow Devices (LFDs) for SARS-CoV-2 for mass community testing./ / Methods: A three-phase evaluation process was established: 1) desktop review of kits including claimed performance and supply; 2) laboratory testing with laboratory-grown SARS-CoV-2 virus and SARS-CoV-2 virus PCR negative volunteer samples; and 3) larger-scale laboratory testing of SARS-CoV-2 PCR positive and negative clinical samples. Variant of Concern (VOC) identification in the UK (December 2020), expanded laboratory methodology. Processes also evolved to improve workflow (irradiated viral stocks, dilution matrices, sample volumes, and replicates)./ / Findings: Overall, 1017 kits were screened at phase 1, 185 kits tested at phase 2 and 91 at phase 3. Sixteen kits failed phase 3 due to poor performance and eight more failed to detect VOC satisfactorily. Sixty-four kits were redesigns of previously failed kits. The overall pass rate for the laboratory evaluation was 35% and 5 kits were procured for the UK National Covid 19 Testing Programme./ / Interpretation: The evaluation results had potential, time limited commercially sensitive aspects, and public sharing was limited to kits passing phase 3. Until now, the full data set has not been published. Over 2.5 billion self-test kits were deployed by the UK government following purchasing decisions informed by this work. We offer a potential blueprint for future evaluation programmes that might be required to assess LFDs to detect cases of a pandemic novel pathogen./ / Funding: This study was funded by UK Department of Health and Social Care (UKHSA); UK Health Security Agency (formerly Public Health England and the National Health Service Test and Trace); and the University of OxfordNIHRBiomedical Research Centre.
Type: | Article |
---|---|
Title: | Laboratory evaluation of 185 commercial assays for detecting SARS-CoV-2: the UK response for mass testing |
Open access status: | An open access version is available from UCL Discovery |
DOI: | 10.1016/j.eclinm.2025.103416 |
Publisher version: | https://doi.org/10.1016/j.eclinm.2025.103416 |
Language: | English |
Additional information: | © The Author(s), 2025. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
Keywords: | Lateral flow device SARS-CoV-2 LFD, Mass-testing, Pandemic, Public health, Coronavirus, Laboratory evaluation, |
UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL |
URI: | https://discovery.ucl.ac.uk/id/eprint/10212978 |
Archive Staff Only
![]() |
View Item |